Outterson, Kevin
Rex, John H.
Article History
Accepted: 4 January 2023
First Online: 11 February 2023
Declarations
:
: KO received no external funding for this work, which is authored in his role as the Austin B Fletcher Professor at the Boston University School of Law. KO is the Principal Investigator of CARB-X, which is funded in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028. CARB-X is also funded by awards from Wellcome (WT224842), Germany’s Federal Ministry of Education and Research (BMBF), the UK Global Antimicrobial Resistance Innovation Fund (GAMRIF) funded by the UK Government Department of Health and Social Care (DHSC), and the Bill & Melinda Gates Foundation. The contents are solely the responsibility of KO and do not necessarily represent the official views of any CARB-X funders. During the period 2019-2022, JHR is Chief Medical Officer & Director, F2G, Ltd., Editor-in-Chief, AMR.Solutions, Operating Partner & Consultant, Advent Life Sciences, and Adjunct Professor of Medicine, McGovern Medical School, Houston, TX; has received grant support from Wellcome Trust; sits (or sat) on the scientific advisory boards of Basilea Pharmaceutica, Novo Holdings, Roche Pharma Research & Early Development, Bugworks Research, Inc., Forge Therapeutics, Inc., Sumitovant, and the AMR Action Fund (AMRAF); and received consulting fees from Forge Therapeutics, Inc., Roivant Sciences, Pfizer Pharmaceuticals, GlaxoSmithKline, and Bugworks Research, Inc. He is currently a shareholder in AstraZeneca Pharmaceuticals, F2G, Ltd, and Advent Life Sciences. The opinions expressed are his own and do not necessarily reflect the opinion of any of the groups with which he works.